145 related articles for article (PubMed ID: 11097480)
1. Type A, but not type B, endothelin receptor antagonists significantly decrease portal pressure in portal hypertensive rats.
De Gottardi A; Shaw S; Sägesser H; Reichen J
J Hepatol; 2000 Nov; 33(5):733-7. PubMed ID: 11097480
[TBL] [Abstract][Full Text] [Related]
2. Endothelin antagonism in portal hypertensive mice: implications for endothelin receptor-specific signaling in liver disease.
Feng HQ; Weymouth ND; Rockey DC
Am J Physiol Gastrointest Liver Physiol; 2009 Jul; 297(1):G27-33. PubMed ID: 19299580
[TBL] [Abstract][Full Text] [Related]
3. Acute effects of endothelin receptor antagonists on hepatic hemodynamics of cirrhotic and noncirrhotic rats.
Cavasin MA; Semus H; Pitts K; Peng Y; Sandoval J; Chapo J; Plato CF
Can J Physiol Pharmacol; 2010 Jun; 88(6):636-43. PubMed ID: 20628429
[TBL] [Abstract][Full Text] [Related]
4. Beneficial hemodynamic effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats.
Sogni P; Moreau R; Gomola A; Gadano A; Cailmail S; Calmus Y; Clozel M; Lebrec D
Hepatology; 1998 Sep; 28(3):655-9. PubMed ID: 9731554
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of endothelin receptors in the vasculature of portal hypertensive rats: role in splanchnic hemodynamics.
Cahill PA; Hou MC; Hendrickson R; Wang YN; Zhang S; Redmond EM; Sitzman JV
Hepatology; 1998 Aug; 28(2):396-403. PubMed ID: 9696003
[TBL] [Abstract][Full Text] [Related]
6. Glytan decreases portal pressure via mesentery vasoconstriction in portal hypertensive rats.
Du QH; Han L; Jiang JJ; Xu Y; Li WH; Li PT; Wang XY; Jia X
World J Gastroenterol; 2014 Nov; 20(44):16674-82. PubMed ID: 25469036
[TBL] [Abstract][Full Text] [Related]
7. Effect of chronic treatment with two different ET(A) selective endothelin receptor antagonists on blood pressure and small artery structure of deoxycorticosterone acetate (DOCA)-salt hypertensive rats.
Li JS; Turgeon A; Schiffrin EL
Am J Hypertens; 1998 May; 11(5):554-62. PubMed ID: 9633791
[TBL] [Abstract][Full Text] [Related]
8. Endothelin a receptor blockade and endothelin B receptor blockade improve hypokalemic nephropathy by different mechanisms.
Suga S; Yasui N; Yoshihara F; Horio T; Kawano Y; Kangawa K; Johnson RJ
J Am Soc Nephrol; 2003 Feb; 14(2):397-406. PubMed ID: 12538740
[TBL] [Abstract][Full Text] [Related]
9. Mixed endothelin receptor antagonist, SB209670, decreases portal pressure in biliary cirrhotic rats in vivo by reducing portal venous system resistance.
Kojima H; Yamao J; Tsujimoto T; Uemura M; Takaya A; Fukui H
J Hepatol; 2000 Jan; 32(1):43-50. PubMed ID: 10673066
[TBL] [Abstract][Full Text] [Related]
10. [Effect and mechanism of salvianolic acid B in attenuating elevated portal pressure in a rat model of portal hypertension induced by endothelin-1].
Zhou Y; Gu J; Xu LM
Zhong Xi Yi Jie He Xue Bao; 2007 Jan; 5(1):61-4. PubMed ID: 17214938
[TBL] [Abstract][Full Text] [Related]
11. Selective endothelin-A versus combined endothelin-A/endothelin-B receptor blockade in rat chronic heart failure.
Mulder P; Boujedaini H; Richard V; Derumeaux G; Henry JP; Renet S; Wessale J; Opgenorth T; Thuillez C
Circulation; 2000 Aug; 102(5):491-3. PubMed ID: 10920058
[TBL] [Abstract][Full Text] [Related]
12. Endothelin-1 induces vasoconstriction on portal-systemic collaterals of portal hypertensive rats.
Chan CC; Wang SS; Lee FY; Chang FY; Lin HC; Chu CJ; Chen CT; Huang HC; Lee SD
Hepatology; 2001 Apr; 33(4):816-20. PubMed ID: 11283844
[TBL] [Abstract][Full Text] [Related]
13. Effects of endothelin receptor antagonists on the plasma immunoreactive endothelin-1 level.
Opgenorth TJ; Wessale JL; Dixon DB; Adler AL; Calzadilla SV; Padley RJ; Wu-Wong JR
J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S292-6. PubMed ID: 11078402
[TBL] [Abstract][Full Text] [Related]
14. Modulation of cardiac natriuretic peptide gene expression following endothelin type A receptor blockade in renovascular hypertension.
Bianciotti LG; de Bold AJ
Cardiovasc Res; 2001 Mar; 49(4):808-16. PubMed ID: 11230980
[TBL] [Abstract][Full Text] [Related]
15. Renal and systemic effects of chronic blockade of ET(A) or ET(B) receptors in normal rats and animals with experimental heart failure.
Francis B; Winaver J; Karram T; Hoffman A; Abassi Z
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S54-8. PubMed ID: 15838359
[TBL] [Abstract][Full Text] [Related]
16. Role of the endothelin system in secondary pulmonary hypertension related to air embolism: lessons learned from testing four classes of endothelin blockers in a rat model.
Battistini B; Verreault M; Ayach B; Blouin A; Cernacek P; Jeng AY; Wessale J; Opgenorth T; Tsang J
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S386-9. PubMed ID: 15838327
[TBL] [Abstract][Full Text] [Related]
17. Hypertension induced by blockade of ET(B) receptors in conscious nonhuman primates: role of ET(A) receptors.
Reinhart GA; Preusser LC; Burke SE; Wessale JL; Wegner CD; Opgenorth TJ; Cox BF
Am J Physiol Heart Circ Physiol; 2002 Oct; 283(4):H1555-61. PubMed ID: 12234809
[TBL] [Abstract][Full Text] [Related]
18. Expression of endothelin receptors in the gastric mucosa of portal hypertensive rats.
Kai S; Bandoh T; Ohta M; Matsumoto T; Tominaga M; Kitano S
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):242-50. PubMed ID: 16460481
[TBL] [Abstract][Full Text] [Related]
19. ABT-627, an endothelin ET(A) receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain.
Jarvis MF; Wessale JL; Zhu CZ; Lynch JJ; Dayton BD; Calzadilla SV; Padley RJ; Opgenorth TJ; Kowaluk EA
Eur J Pharmacol; 2000 Jan; 388(1):29-35. PubMed ID: 10657544
[TBL] [Abstract][Full Text] [Related]
20. Endothelin-1 plays a major role in portal hypertension of biliary cirrhotic rats through endothelin receptor subtype B together with subtype A in vivo.
Kojima H; Sakurai S; Kuriyama S; Yoshiji H; Imazu H; Uemura M; Nakatani Y; Yamao J; Fukui H
J Hepatol; 2001 Jun; 34(6):805-11. PubMed ID: 11451162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
